Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | ICMT | O60725 | 3/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918202 | 0.91 | TRPV4 (0.36) | TRPV4ICMTPTGDR2HTR2ASLC6A4 | |
| SCHEMBL9918824 | 0.87 | HPGD (0.39) | — | |
| SCHEMBL9918843 | 0.85 | AR (0.40) | TRPV4ICMTSLC6A4AR | |
| SCHEMBL9918828 | 0.82 | BRPF1 (0.32) | — | |
| SCHEMBL12302988 | 0.79 | TRPV4 (0.38) | TRPV4ICMTPTGDR2HTR2ASLC6A4 | |
| SCHEMBL18896348 | 0.79 | TRPV4 (0.36) | TRPV4ICMTPTGDR2HTR2ASLC6A4 | |
| SCHEMBL18599183 | 0.77 | TP53 (0.38) | — | |
| SCHEMBL9918207 | 0.77 | TP53 (0.38) | — | |
| SCHEMBL12251265 | 0.76 | TRPV4 (0.34) | TRPV4ICMTPTGDR2HTR2ASLC6A4 | |
| SCHEMBL9918204 | 0.76 | AR (0.42) | TRPV4ICMTSLC6A4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | TRPV4 3728/4885ICMT 3532/4885PTGDR2 2002/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | TRPV4 3787/4885ICMT 3334/4885PTGDR2 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.